Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone

Bone

Volumn 28, Issue 4, 2001, Pages 370-377

  Atkins, G J ^a   Bouralexis, S ^a   Haynes, D R ^a   Graves, S E ^b   Geary, S M ^c   Evdokiou, A ^a   Zannettino, A C W ^c   Hay, S ^a   Findlay, D M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Bone; Giant cell tumor (GCT); Osteoclast; Osteoprotegerin (OPG); Receptor activator nuclear factor of B ligand (RANKL)

Indexed keywords

ACID PHOSPHATASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOPROTEGERIN; RECOMBINANT IMMUNOGLOBULIN ENHANCER BINDING PROTEIN LIGAND; RECOMBINANT OSTEOPROTEGRIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOPLASM; DOSE RESPONSE; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; OSTEOCLAST; OSTEOCLASTOMA; OSTEOLYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SYNTHESIS; STROMA CELL; TUMOR CELL CULTURE;

BONE NEOPLASMS; BONE RESORPTION; CARRIER PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE; GIANT CELL TUMOR OF BONE; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MICROSCOPY, ELECTRON, SCANNING; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0035040250     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(01)00404-5     Document Type: Article

References (34)

1. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy
2. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
3. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors
4. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
5. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
6. Osteoclasts are required for bone tumors to grow and destroy bone
7. Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy
8. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
9. Human giant cell tumors of the bone; Identification and characterization of cell types
10. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis
11. The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases
12. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone; Possible involvement in tumor cell-induced osteoclast-like cell formation
13. Purification and characterization of fully functional osteoclast precursors
14. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function
15. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
16. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
17. Interleukins in the control of osteoclast differentiation
18. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures
19. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
20. Osteoprotegerin prevents osteolytic bone destruction in both athymic and syngeneic models of experimental tumor metastasis to bone
21. Expression of functional RANK on mature rat and human osteoclasts
22. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis
23. Osteoclasts constitutively express regulators of bone resorption; An immunohistochemical and in situ hybridization study
24. Mechanisms of bone lesions in multiple myeloma and lymphoma
25. Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8
26. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors
27. Osteoprotegerin; A novel secreted protein involved in the regulation of bone density
28. Breast cancer cells interact with osteoblasts to support osteoclast formation
29. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
30. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG); A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
31. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL
32. + macrophage-like cell migration